Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...

A Northwestern Medicine study published in Nature Communications has revealed how HIV can protect infected cells by altering ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

In a randomized trial, ART intensification by doubling the dolutegravir dosage in people with HIV stably suppressed on ...

In a groundbreaking discovery, researchers from Florida Atlantic University's Charles E. Schmidt College of Medicine have identified a never-before-seen mechanism that enables the human ...

Human immunodeficiency virus (HIV) infections are lifelong, potentially life-threatening infections that weaken an individual’s immune system, rendering them susceptible to severe secondary infections ...

In 2022, there were up to 1.2 million people with HIV (PWH) and 37,981 new cases of HIV in the United States alone. 1 While impressive advances have been made in HIV treatment and prevention, there ...